Neuronetics, Inc. (NASDAQ:STIM) EVP Sells $46,630.25 in Stock

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) EVP William Andrew Macan sold 12,175 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $46,630.25. Following the transaction, the executive vice president now owns 388,647 shares of the company's stock, valued at $1,488,518.01. This represents a 3.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

William Andrew Macan also recently made the following trade(s):

• On Monday, February 10th, William Andrew Macan sold 1,970 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $6,461.60.

Neuronetics Stock Performance

Neuronetics stock traded up $0.35 during mid-day trading on Tuesday, hitting $4.71. 1,482,011 shares of the company's stock traded hands, compared to its average volume of 1,628,062. The firm has a 50 day moving average price of $2.27 and a 200 day moving average price of $1.43. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The company has a market cap of $142.80 million, a PE ratio of -3.83 and a beta of 2.17. Neuronetics, Inc. has a one year low of $0.52 and a one year high of $5.07.

Institutional Trading of Neuronetics

Hedge funds have recently added to or reduced their stakes in the business. Tradewinds LLC. bought a new stake in shares of Neuronetics in the 4th quarter worth $32,000. XTX Topco Ltd bought a new stake in shares of Neuronetics in the 4th quarter worth $49,000. Landscape Capital Management L.L.C. bought a new stake in shares of Neuronetics in the 3rd quarter worth $53,000. GSA Capital Partners LLP raised its stake in shares of Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after buying an additional 30,837 shares in the last quarter. Finally, David J Yvars Group raised its stake in shares of Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company's stock worth $75,000 after buying an additional 14,825 shares in the last quarter. Institutional investors own 53.59% of the company's stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.